Vnitřní lékařství 1/2020

PŘEHLEDOVÉ ČLÁNKY Monitorovanie a individualizácia liečby inhibítormi P2Y12 ADP receptorov 32 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(E-1): 26–33 /  www.casopisvnitrnilekarstvi.cz 16. Fedor M, Samoš M, Šimonová R, et al. Monitoring the efficacy of ADP inhibitor tre- atment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. Clin Appl Thromb Hemost 2015; 4: 334–338. 17. Samoš M, Fedor M, Kovář F, et al. Ticagrelor: a safe and effective approach for over- coming clopidogrel resistance in patients with stent thrombosis? Blood Coagul Fibrino- lysis 2016; 2: 117–120. 18. Bolek T, Samoš M, Šimonová R, et al. Does Pantoprazole Affect the On-Treatment Pla- telet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?-A Pi- lot Prospective Study. Am J Ther 2017; 2: e162–e166. 19. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregomet- ry for the assessment of clopidogrel action using the novel Multiplate analyzer – compa- rison with two flow cytometric methods. Thromb Res 2007; 121: 249–258. 20. Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance ag- gregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008; 107: 1798–1806. 21. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment asse- ssed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Car- diol 2009; 53: 849–856. 22. Consuegra-Sánchez L, López-Palop R, Cano P, et al. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multi­ plate and VerifyNow assays. J Thromb Haemost 2013; 2: 379–381. 23. Verdoia M, Barbieri L, Suryapranata H, et al. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. Platelets 2016; 27: 93–104. 24. Lundström A, Wallén H, von Arbin M, et al. Clopidogrel Resistance after Minor Ische- mic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small- -Vessel Disease. J Stroke Cerebrovasc Dis 2015; 10: 2348–2357. 25. Bernlochner I, Jaitner J, Fries V, et al. High on-treatment platelet reactivity and outco- mes after percutaneous endovascular procedures in patients with peripheral artery di- sease. Vasa 2016; 45: 155–161. 26. Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with tri- ple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009; 134: 351–355. 27. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel re- sistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009; 104: 525–530. 28. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment plate- let reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Main- tenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101–1109. 29. Campo G, Fileti L, de Cesare N, et al. 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous co- ronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resi- stance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56: 1447–1455. 30. Jang J, Lim J, Chang K, et al. A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percuta- neous coronary intervention. J Clin Lab Anal 2012; 26: 262–266. 31. Fifi JT, Brockington C, Narang J, et al. Clopidogrel resistance is associated with throm- boembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013; 34: 716–720. 32. Nordeen JD, Patel AV, Darracott RM, et al. Clopidogrel Resistance by P2Y12 Platelet Fun- ction Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ische- mic and Hemorrhagic Complications. J Vasc Interv Neurol 2013; 6: 26–34. 33. Leunissen TC, Peeters Weem SM, Urbanus RT, et al. High On-Treatment Platelet Reac- tivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Va- lues. Eur J Vasc Endovasc Surg 2016; 52: 198–204. 34. Collet JP, Cuisset T, Rangé G, et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100–2109. 35. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coro- nary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Tes- ting Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159–2164. 36. Bagai A, Peterson ED, McCoy LA, et al. Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndro- me (TRANSLATE-ACS) study. Am Heart J 2017; 187: 19–28. 37. Jung HJ, Sir JJ. Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance. J Invasi- ve Cardiol 2011; 23: E15–E18. 38. Bouman HJ, van Werkum JW, Breet NJ, et al. A case-control study on platelet reac- tivity in patients with coronary stent thrombosis. J Thromb Haemost 2011; 9: 909–916. 39. Rajendran S, Parikh D, Shugman I, et al. High on treatment platelet reactivity and stent thrombosis. Heart Lung Circ 2011; 20: 525–531. 40. Gaglia MA, Torguson R, Pakala R, et al. Correlation between light transmission aggre- gometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 2011; 24: 529–534. 41. Fedor M, Šimonová R, Fedorová J, et al. Role of VASP phosphorylation assay in moni- toring the antiplatelet therapy. Acta Medica Martiniana 2013; 13: 21–26. 42. Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabo- lite of clopidogrel. J Thromb Haemost 2010; 8: 482–488. 43. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85–92. 44. Remková A, Janušicová A, Remko M. Is antiplatelet therapy always effective? Vnitř Lék 2012; 58: 904–914. 45. Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST- -segment elevation acute coronary syndrome. Thromb Res 2007; 120: 893–899. 46. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter ran- domized prospective study. J Am Coll Cardiol 2008; 51: 1404–1411. 47. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphopro- tein phosphorylation analysis prior to percutaneous coronary intervention for exc- lusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630–1636. 48. Cuisset T, Frere C, Poyet R, et al. Clopidogrel response: head-to-head comparison of di- fferent platelet assays to identify clopidogrel non responder patients after coronary sten- ting. Arch Cardiovasc Dis 2010; 103: 39–45. 49. El Ghannudi S, Ohlmann P, Meyer N, et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angi- oplasty: a prospective registry. JACC Cardiovasc Interv 2010; 3: 648–656. 50. Zhang S, Lai X, Li W, et al. VASP phosphorylation and genetic polymorphism for clopi- dogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. Thromb Res 2014; 134: 1272–1277. 51. Ari H, Ozkan H, Karacinar A, et al. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 2012; 157: 374–380. 52. Collet JP, Hulot JS, Anzaha G, et al. CLOVIS-2 Investigators. High doses of clopido- grel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4: 392–402. 53. Choi H, Ryu J, Seo H, et al. Is a high maintenance dose of clopidogrel suitable for over- coming clopidogrel resistance in patients? Int J Clin Pharm 2015; 37: 758–761. 54. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outco- mes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVI- TAS) trial. Circulation 2011; 124: 1132–1137. 55. Diodati JG, Saucedo JF, Cardillo TE, et al. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thromb Haemost 2014; 112: 311–322. 56. Valenti R, Marcucci R, Comito V, et al. Prasugrel in Clopidogrel Nonresponders Under- going Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLO- pidogrel and StEnt Thrombosis). JACC Cardiovasc Interv 2015; 8: 1563–1570. 57. Park SD, Lee MJ, Baek YS, et al. Randomised trial to compare a protective effect of Clo- pidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myo- cardial infarction (CV-TIME trial). EuroIntervention 2016; 12: e964–e971. 58. Yao G, Su G, Li K, et al. Comparative study of ticagrelor and clopidogrel in therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary inter- vention. Saudi J Biol Sci 2017; 24: 1818–1820. 59. Sardella G, Calcagno S, Mancone M, et al. Comparison of therapy with Ticagrelor, Pra- sugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. Int J Cardiol 2015; 194: 60–62. 60. Behr T, Kuch B, Behr W, et al. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clin Res Cardiol 2011; 100: 907–914. 61. Kim BK, Oh SJ, Yoon SJ, et al. A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. Yonsei Med J 2011; 52: 717–726. 62. Ha SJ, Kim SJ, Hwang SJ, et al. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary inter- vention. Coron Artery Dis 2013; 24: 690–697.